A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans-Tasman Radiation Oncology Group (TROG)
Participating Centres
Accrual Target
32
Current Accrual
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
February 28, 2022
Cancer trial participant hoping to help
The RAVES trial treating prostate cancer Participating in a
June 15, 2021
Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery
Ductal carcinoma in situ (DCIS) of the breast is
